Literature DB >> 8878127

Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.

K H Bohuslavizki1, W Brenner, S Lassmann, S Tinnemeyer, G Tönshoff, C Sippel, H Wolf, M Clausen, E Henze.   

Abstract

This study was undertaken to quantify salivary gland parenchymal damage after radioiodine treatment with a standard protective regimen of ascorbic acid. Altogether, 106 patients underwent quantitative salivary gland scintigraphy with 99Tcm-pertechnetate prior to and 3 months after radioiodine therapy. Parenchymal function was quantified by calculating 99Tcm-pertechnetate uptake 13 min post-injection. Patients received 131I doses ranging from 400 MBq to 24 GBq (cumulative). Among the patients who received large doses of 131I, severe parenchymal destruction could be visually analysed as well as quantitatively evaluated. In contrast, after low-dose radioiodine treatment, mild parenchymal impairment was demonstrated by quantitative evaluation only. In conclusion, standardized quantitative salivary gland scintigraphy is essential for the reliable detection of mild parenchymal malfunction. Despite the standard protection regimen using ascorbic acid as a sialogogue, radioiodine therapy induces loss of salivary gland parenchymal function even with low doses of 131I.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878127     DOI: 10.1097/00006231-199608000-00006

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  14 in total

1.  Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.

Authors:  B Nabaa; K Takahashi; T Sasaki; A Okizaki; T Aburano
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-03       Impact factor: 3.825

Review 2.  Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Zhongxin Jiang; Guoming Wang; Shuyao Zuo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-04       Impact factor: 9.236

3.  Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.

Authors:  K H Bohuslavizki; S Klutmann; C Bleckmann; W Brenner; S Lassmann; J Mester; E Henze; M Clausen
Journal:  Strahlenther Onkol       Date:  1999-02       Impact factor: 3.621

4.  Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.

Authors:  Shin Young Jeong; Hae Won Kim; Sang-Woo Lee; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

5.  Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model.

Authors:  Jeong-Seok Choi; In Suh Park; Seok-Ki Kim; Jae-Yol Lim; Young-Mo Kim
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

6.  The Role of Salivary Gland Scintigraphy in the Evaluation of Salivary Gland Dysfunction in Uncontrolled Type II Diabetic Patients.

Authors:  B Senthilkumar; S Sathasivasubramanian
Journal:  World J Nucl Med       Date:  2013-09

7.  Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Authors:  Walter Jentzen; Robert F Hobbs; Alexander Stahl; Jochen Knust; George Sgouros; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

8.  A Functional Scoring System Based on Salivary Gland Scintigraphy for Evaluating Salivary Gland Dysfunction Secondary to 131I therapy in Patients with Differentiated Thyroid Carcinoma.

Authors:  Yasuhiro Maruoka; Shingo Baba; Takuro Isoda; Yoshiyuki Kitamura; Koichiro Abe; Masayuki Sasaki; Hiroshi Honda
Journal:  J Clin Diagn Res       Date:  2017-08-01

9.  The role of salivary gland scintigraphy in detection of salivary gland dysfunction in type 2 diabetic patients.

Authors:  Balasubramanian Senthil Kumar; Sankara Pandian Sathasivasubramanian
Journal:  Indian J Nucl Med       Date:  2012-01

10.  Early Quantification of Salivary Gland Function after Radioiodine Therapy.

Authors:  Karan Singh Tanwar; Nivedita Rana; Bhagwant Rai Mittal; Anish Bhattacharya
Journal:  Indian J Nucl Med       Date:  2021-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.